retatrutide ly3437943 triple agonist gip glp-1 glucagon mechanism Retatrutide is not “just another GLP1.” It LY3437943, a novel triple GIP,

Weight loss via GLP-1s like Ozempic ($17.45B in 2024 sales, up 25% YoY) proved even more lucrative than erectile dysfunction, with Ro's GLP-1 sales 3x'ing between January 2023 and August 2024, pushing topline growth to 66% in 2024 (vs 14% in 2023 and 5% in 2022) and lifting average transaction value from ~$93 to ~$134, while Hims & Hers hit 100K GLP-1 members and ~$343M in annualized GLP-1 revenue by the end of 2024

not recommended for new market entry)

About this article Cite this article Li, Z., Lu, J., Dong, Z

Regular NAC supplements are cheaper and more stable, but depend on a well-functioning conversion process

PlexusDx partners exclusively with licensed 503A compounding pharmacies, ensuring continuous medication availability across all 50 states without membership fees or supply-chain volatility